

**Details of the ESOPs as per the provisions of Section 62 of the Companies Act, 2013, read with Rule 12 of The Companies (Share Capital and Debentures) Rules, 2014 and Regulation 14 of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 read with SEBI circular dated June 16, 2015.**

- A. The information pursuant to the provisions of Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, erstwhile SEBI (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999 read with 'Guidance note on accounting for Employee share-based payments' issued by ICAI is covered in the Notes to Financial Statements
- B. Information regarding Diluted EPS on issue of shares pursuant to all the schemes covered under the regulations in accordance with 'Accounting Standard 20 - Earnings Per Share' issued by ICAI is covered in the Notes to Financial Statements

**Summary of Status of ESOPs Granted**

The position of the existing schemes is summarized as under -

| SR.NO.   | PARTICULARS   | ESOS 2010   |
|--|---|---|
| <b>I.</b>  | <b>Details of the ESOS that existed anytime during the year</b>   |   |
| 1  | Date of Shareholder's Approval                                    | July 24,2010  |
| 2  | Total Number of Options approved under ESOS                       | 5,00,000  |
| 3  | Vesting Requirements  | Not less than one year from the date of grant   |
| 4  | Exercise Price or Pricing formula (₹)                             | The Compensation Committee shall have the freedom to determine the Exercise Price, subject to compliance by the Company with the accounting policies as may be specified from time to time. |
| 5  | Maximum term of Options granted (years)                           | 5 years   |
| 6  | Source of shares (Primary, Secondary or combination)              | Primary   |
| 7  | Variation in terms of options                                     | No variation/modification/amendment was made in the terms of options during the financial year 2022-23  |
| <b>II.</b>   | <b>Method used to account for ESOS</b>                            |   |
| The Company has calculated the employee compensation cost using the fair valuation (Black Scholes) method of accounting for the Options granted under the Scheme |   |   |
| <b>III.</b>  | <b>Option Movement during the year</b>                            |   |
|  |   | <b>ESOS 2010</b>  |
| 1  | Number of Options Outstanding at the beginning of the year        | 2,80,000  |
| 2  | Number of Options Granted during the year                         | -   |
| 3  | Number of Options Forfeited / lapsed during the year              | -   |
| 4  | Options Lapsed during the year                                    | -   |
| 5  | Number of Options Vested during the year                          | -   |
| 6  | Number of Options Exercised during the year                       | 14,350  |
| 7  | Total number of shares arising as a result of exercise of options | 14,350  |
| 8  | Money realized by exercise of options (Rs.)                       | 35,87,500   |
| 9  | Number of options Outstanding at the end of the year              | 2,65,650  |
| 10   | Number of Options exercisable at the end of the year              | -   |

| <b>IV. Weighted average exercise price of Options granted during the year whose</b>  |  |  |  |
|--|--|--|--|
| (a)  | Exercise price equals market price   | Please refer to the Note No. 35 of the Standalone Financials Statements and note no. 35 of the Consolidated Financial Statements of the Company for the financial year ended March 31, 2023. |  |
| (b)  | Exercise price is greater than market price  |  |  |
| (c)  | Exercise price is less than market price   |  |  |
| <b>Weighted average fair value of options granted during the year whose:</b>   |  |  |  |
| (a)  | Exercise price equals market price   | Please refer to the Note No. 35 of the Standalone Financials Statements and note no. 35 of the Consolidated Financial Statements of the Company for the financial year ended March 31, 2023. |  |
| (b)  | Exercise price is greater than market price  |  |  |
| (c)  | Exercise price is less than market price   |  |  |
| <b>V. Employee-wise details of options granted during the year 2023</b>  |  |  |  |
| (i)  | <b>Senior managerial personnel :</b>   |  |  |
|  | <b>Name of Employees</b>   | <b>Designation</b>   | <b>Number of Options granted during the year (ESOS 2010)</b> |
|  |  |  | <b>Exercise price (Rs.)</b>                                  |
| (ii)   | Details with respect to the grants made to the Senior management personnel shall be made available to the Members based on a request received by the Company at <a href="mailto:investor@reproindia ltd.com">investor@reproindia ltd.com</a> |  |  |
|  | <b>Employees who were granted, during the year, options amounting to 5% or more of the options granted during the year 2022</b>  |  |  |
|  | <b>Name of Employees</b>   | <b>Designation</b>   | <b>Number of Options granted during the year</b>             |
|  |  |  | <b>Exercise price (Rs.)</b>                                  |
| (iii)  | NONE   |  |  |
|  | <b>Identified employees who were granted option, during the year equal to or exceeding 1% of the issued capital (excluding outstanding warrants and conversions) of the company at the time of grant.</b>                                    |  |  |
|  | <b>Name of Employees</b>   | <b>Designation</b>   |  |
|  | NONE   |  |  |
| <b>VI. Method and Assumptions used to estimate the fair value of options granted during the year:</b>  |  |  |  |
| The fair value has been calculated using the Black Scholes Option Pricing model  |  |  |  |
| The Assumptions used in the model are as follows:  |  |  |  |
|  | <b>Particulars of options granted</b>  | <b>ESOSP 2010</b>  |  |
|  | 1. Date of Grant   | Please refer to the Note No. 35 of the Standalone Financials Statements and note no. 35 of the Consolidated Financial Statements of the Company for the financial year ended 31 March, 2023  |  |
|  | 2. Risk Free Interest Rate   |  |  |
|  | 3. Expected Life   |  |  |
|  | 4. Expected Volatility   |  |  |
|  | 5. Dividend Yield  |  |  |
|  | 6. Price of the underlying share in market at the time of the option grant (Rs.)   |  |  |
| <b>Assumptions:</b>  |  |  |  |
| Volatility: The historical volatility over the expected life has been considered to calculate the fair value.  |  |  |  |
| Risk-free rate of return: The risk-free interest rate being considered for the calculation is the interest rate applicable for a maturity equal to the expected life of the options based on the zero Exercise Price: Exercise Price of each specific grant has been considered. |  |  |  |
| Time to Maturity: Time to Maturity / Expected Life of options is the period for which the Company expects the options to be live.  |  |  |  |
| Expected divided yield: Expected dividend yield has been calculated as an total of Interim and final divined declared in last year preceding date of Grant   |  |  |  |